Yes / Advanced drug delivery systems, such as ultrasound-mediated drug delivery, show great promise for increasing the therapeutic index. Improvements in delivery by altering the ultrasound parameters have been studied heavily in vitro but relatively little in vivo. Here, the same therapeutic microbubble and tumour type are used to determine whether altering ultrasound parameters can improve drug delivery. Liposomes were loaded with SN38 and attached via avidin: biotin linkages to microbubbles. The whole structure was targeted to the tumour vasculature by the addition of anti-vascular endothelial growth factor receptor 2 antibodies. Tumour drug delivery and metabolism were quantified in SW480 xenografts after application of an ultrasound trigger to the tumour region. Increasing the trigger duration from 5 s to 2 min or increasing the number of 5 s triggers did not improve drug delivery, nor did changing to a chirp trigger designed to stimulate a greater proportion of the microbubble population, although this did show that the short tone trigger resulted in greater release of free SN38. Examination of ultrasound triggers in vivo to improve drug delivery is justified as there are multiple mechanisms at play that may not allow direct translation from in vitro findings. In this setting, a short tone burst gives the best ultrasound parameters for tumoural drug delivery. / This research was funded by the EPSRC (EP/I000623/1, EP/L504993/1 and EP/P023266/1). S.D.E. is supported by the National Institute for Health Research infrastructure at Leeds. J.R.M. is supported by an EPSRC UKRI Innovation Fellowship (EP/S001069/1).

No description available.

No description available.

Luminescent quantum dot (QD) based probes have gained significance in the last decade for optical imaging of cells, tissues and in bioassays as alternatives to conventional organic fluorophores. The main objective of my PhD dissertation was to develop luminescent quantum dot based bioassays for real time monitoring of enzyme activity and simultaneous detection of several biomarkers. The quantum dot based bioassays developed will be potential tools in identification and diagnosis of several ailments that interfere with normal living conditions of human beings. In Chapter 2 new liposome encapsulated quantum dot based fluorescence resonance energy transfer (FRET) probes have been fabricated and characterized for monitoring the enzymatic activity of phospholipase A 2. The probes were able to detect the enzyme activity as low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min. Further these FRET probes were also used to screen the inhibition efficiencies of phospholipase A2 inhibitors. Chapter 3 focuses on the first time synthesis and characterization of liposome encapsulated InP/ZnS quantum dots while preserving the integrity of the liposomes. Results from the experiments to assess photostability and effect of pH on the optical properties of InP/ZnS QD-liposomes showed greater advantages over InP/ZnS quantum dots demonstrating their utility as a potential tool in several biological applications such as bio imaging, bioassays and in immunoassays. Chapter 4 discusses the development of fluorescence based immunoassay for simultaneous detection of the cardiac biomarkers troponin T and troponin I using CdSe/ZnS quantum dots. The assay achieved a detection limit was 0.1 pg/mL for both biomarkers troponin xi T and I. The method was highly specific for the both the biomarkers with no observed cross reactivity. The multiplex assay was able to detect two biomarkers simultaneously that will yield a high throughput diagnostic tool for heart attack. A similar method discussed as above was used in chapter 5 for the simultaneous detection of atherosclerosis biomarkers. The detection limits achieved in this study are comparable to the detection limits of the biomarkers reported so far. Incorporation of QDs in silica beads before conjugation to antibodies might improve detection limits that will also improve risk assessment.

Ces travaux de thèse ont porté sur le développement de formulations innovantes et nanoparticulaire, destinées à améliorer la prise en charge des patients atteints de leucémie aigüe myéloïdes (LAM). Cette amélioration de la qualité de vie peut passer par le développement d’une formulation orale de décitabine.Trois stratégies de formulations différentes ont été développées : deux formulations de nanocapsules lipides (LNCs) avec encapsulation ou de décitabine, ou d’une prodrogue de décitabine (décitabine(C12)2) . La troisième stratégie a été le développement de particules de type liposomal, dans lesquelles la décitabine a été encapsulée. Après avoir été caractérisée sur des critères physicochimiques, chacune des stratégies basées sur les LNCs a été évaluée par des essais in vitro pour évaluer la perméabilité intestinale de la décitabine lorsqu’elle a été encapsulée. Une des stratégies a permis d’accroitre la perméabilité, in vitro, de la décitabine. L’activité sur la prolifération cellulaire a ensuite été évaluée sur des cellules humaines de LAM. Il a été démontré que l’encapsulation dans les LNCs améliore l’activité de la décitabine et de la décitabine (C12)2. Après l’ensemble de ces essais, en vue d’évaluer le potentiel avantages de ces formulations pour augmenter la demi-vie plasmatique de la décitabine, leurs stabilités dans du plasma humain a été évaluée. La décitabine (C12)2 libre et encapsulée permettent de limiter la dégradation rapide de la décitabine. Finalement, une étude de pharmacocinétique a été mise en place. L’encapsulation de la décitabine, en synthétisant au préalable une prodrogue permet d’augmenter les concentrations maximales atteintes. / The aim of this phD work was to develop nanoparticle formulations to improve patients’quality of life in case of acute myeloid leukemia (AML). These formulations could, for example, allow an oral administration of decitabine. Three different formulations were developed: two were based on lipid nanocapsules (LNCs) with an encapsulation of decitabine or a decitabine prodrug (decitabine(C12)2). The third strategy was aliposomal formulation with a decitabine encapsulation. After being characterized on physico-chemical parameters, in vitro intestinal permeability studies were performed on LNCs strategies. One strategy was able to enhance decitabine permeability. Cell proliferation studies performed on human AMLcell lines showed that encapsulations into LNCs improve decitabine and decitabine(C12)2 activities. In order to evaluate the potential of these formulations to enhance decitabine plasma half-life, their stabilities in human plasma were then assayed. Free decitabine(C12)2 or encapsulated into LNCs has been shown to limit the rapid decitabine degradation. Finally, pharmacokinetic studies were performed. Decitabine encapsulation into LNCs with a previous decitabine prodrug synthesis was able to increase maximal plasma concentrations.

<p>This thesis describes results from fundamental studies of liposomes intended for drug delivery and pH or temperature triggered release. In addition, the effect of lipid composition on bilayer disc formation and a potential application of the bilayer discs were investigated.</p><p>The lower pH encountered by endocytosed liposomes can be utilized to trigger drug release. The mechanisms behind cytosolic drug delivery were investigated using two different kinds of pH-sensitive liposomes. The results indicate that incorporation of non-lamellar forming lipids into the endosome membrane may allow for drug escape into the cytosol.</p><p>Temperature-sensitive liposomes containing lysolipid (LTSL) release their content almost instantly when heated to temperatures close to the gel to liquid crystalline phase transition temperature (T<i>C</i>). Morphological changes of the liposomes in response to temperature cycling were studied. Temperature cycling induced liposome openings and disintegration of the liposomes into bilayer discs. Incubation of LTSL in the presence of multilamellar liposomes (MLVs) resulted in relocalisation of lysolipid into the MLVs, which affected the rapid release from LTSL. We propose that the presence of micelle-forming components, such as lysolipids and PEG-lipids, facilitates the formation of defects and membrane openings during the initial phase of membrane melting, resulting in the observed rapid release. Similar to added lysolipids, also hydrolysis generated lysolipids induce disc-formation upon heating through T<i>C</i> of the lipid mixture.</p><p>Two fundamentally different micelles may form in PEG-lipid/lipid mixtures. We found that discoidal structures are preferred over cylindrical micelles when the mixture contains components that reduce the spontaneous curvature, increase the monolayer bending modulus, or reduce PEG-lipid/lipid miscibility. The large discoidal micelles found at low PEG-lipid content are better described as bilayer discs. We evaluated such discs as model membranes in drug partitioning studies, and suggest that they, in some cases, produce more accurate data than liposomes.</p>

This thesis describes results from fundamental studies of liposomes intended for drug delivery and pH or temperature triggered release. In addition, the effect of lipid composition on bilayer disc formation and a potential application of the bilayer discs were investigated. The lower pH encountered by endocytosed liposomes can be utilized to trigger drug release. The mechanisms behind cytosolic drug delivery were investigated using two different kinds of pH-sensitive liposomes. The results indicate that incorporation of non-lamellar forming lipids into the endosome membrane may allow for drug escape into the cytosol. Temperature-sensitive liposomes containing lysolipid (LTSL) release their content almost instantly when heated to temperatures close to the gel to liquid crystalline phase transition temperature (TC). Morphological changes of the liposomes in response to temperature cycling were studied. Temperature cycling induced liposome openings and disintegration of the liposomes into bilayer discs. Incubation of LTSL in the presence of multilamellar liposomes (MLVs) resulted in relocalisation of lysolipid into the MLVs, which affected the rapid release from LTSL. We propose that the presence of micelle-forming components, such as lysolipids and PEG-lipids, facilitates the formation of defects and membrane openings during the initial phase of membrane melting, resulting in the observed rapid release. Similar to added lysolipids, also hydrolysis generated lysolipids induce disc-formation upon heating through TC of the lipid mixture. Two fundamentally different micelles may form in PEG-lipid/lipid mixtures. We found that discoidal structures are preferred over cylindrical micelles when the mixture contains components that reduce the spontaneous curvature, increase the monolayer bending modulus, or reduce PEG-lipid/lipid miscibility. The large discoidal micelles found at low PEG-lipid content are better described as bilayer discs. We evaluated such discs as model membranes in drug partitioning studies, and suggest that they, in some cases, produce more accurate data than liposomes.

La présence de la glycoprotéine P (P-gp) dans la barrière hémato-encéphalique (BHE) conduit à l’échec de nombreuses thérapies ciblant le système nerveux central (SNC). Cependant la P-gp protège aussi le cerveau contre des composés nocifs, essentiellement lipophiles, endogènes et exogènes susceptibles de passer la BHE par diffusion simple. Par conséquent, toute inhibition de la P-gp qui vise à améliorer la distribution des agents pharmacologiques dans le cerveau doit prendre en compte la neurotoxicité potentielle de cette inhibition. Les premiers travaux ont montré que l’elacridar et le tariquidar, deux modulateurs de la P-gp de troisième génération, augmentaient la distribution dans le cerveau de plusieurs de ses substrats. Malheureusement, d’autres études plus récentes, suggèrent l’utilisation de doses élevées de l’elacridar et du tariquidar pour moduler efficacement l’activité de la P-gp dans la BHE. Néanmoins, ces doses élevées en co-administration avec des substrats de la P-gp peuvent être associées à des interactions pharmacocinétiques et à des profils toxiques, limitant ainsi l'utilisation de ces inhibiteurs.Dans ce contexte, l’objectif principal de cette thèse est d’obtenir une modulation transitoire mais efficace de la P-gp dans la BHE par administration intraveineuse de doses faibles mais thérapeutiques de l’elacridar et du tariquidar sous leur forme libre ou co-encapsulé dans les liposomes. Le lopéramide, substrat de la P-gp, a été également administré sous sa forme libre comme une preuve in vivo d’une inhibition efficace de la P-gp dans la BHE.L'administration simultanée de ces deux modulateurs de la P-gp n’a pas modifié leurs concentrations plasmatiques ou celles du lopéramide, mais a entraîné une importante distribution du lopéramide dans le cerveau en raison de leur activité inhibitrice non- compétitive. De plus, la co-encapsulation de l’elacridar et du tariquidar dans des immunoliposomes stabilisées stériquement a amélioré la demi-vie et la distribution dans le cerveau des ceux deux composés. Par conséquent, la distribution dans le cerveau du lopéramide a été considérablement augmentée, sans aucune modification de sa pharmacocinétique ou distribution tissulaire. Par ailleurs, la diminution partielle de l'activité inhibitrice du tariquidar par des liposomes vides suggère l’utilisation de ce nanovecteur comme une approche de bio-détoxification pour le traitement des surdoses de tariquidar. En résumé, cette thèse propose différentes approches pour exploiter pleinement l’elacridar et le tariquidar. Les résultats décrits dans ce manuscrit devraient ouvrir des pistes intéressantes pour atteindre une inhibition efficace de la P-gp dans la BHE et pour réussir des thérapies ciblant le système nerveux central / Although the P-glycoprotein (P-gp) represents an obstacle in several central nervous system (CNS) pharmacotherapies, the P-gp also protects the brain from intoxication by endogenous and exogenous harmful lipophilic compounds that otherwise could penetrate the blood-brain barrier (BBB) by simple diffusion. Therefore, any modulation of the efflux transporter has to consider the potential neurotoxicity of such modulation. Early studies showed that elacridar and tariquidar, two third-generation P-gp modulators, increase the distribution of several P-gp substrates in the brain. Unfortunately, recent studies suggest the use of high doses of elacridar and tariquidar to efficiently modulate the P-gp at the BBB. Nevertheless, when co-administered with P-gp substrates, these high doses may be associated with pharmacokinetic interactions and toxic profiles, thus limiting the use of these compounds.Hence, this thesis aimed to attain a transient but efficient modulation of the P-gp at the BBB using elacridar and tariquidar but avoiding the use of large doses of these compounds. For this purpose we took advantage of the possible in vivo intravenous co-administration of low but therapeutic doses of elacridar and tariquidar, under their free form or co-encapsulated in liposomes. The brain distribution of free loperamide was determined as an in vivo probe of full inhibition of the P-gp activity at the BBB.The concurrent administration of both free P-gp modulators does not modify their plasma concentrations or those of the P-gp substrate but significantly increased the brain uptake of loperamide as a result of their non-competitive modulatory activity. Moreover, the co-encapsulation of elacridar and tariquidar in targeted sterically stabilized immunoliposomes improved the half-lives and brain distribution of both compounds. Consequently, the brain uptake of free loperamide was significantly enhanced without any modification of its pharmacokinetics or tissue distribution. Moreover, the partial impairment of the modulatory activity of tariquidar by empty liposomes, supports the use of this nanocarrier as a bio-detoxifying approach for the treatment of tariquidar overdoses.In summary, this thesis proposes different approaches for full exploitation of elacridar and tariquidar. The findings described in this manuscript should open interesting avenues to achieve an efficient overcoming of the P-gp at the BBB and succeed CNS pharmacotherapies.

Liposomal nanocarriers offer much promise in chemotherapeutic drug delivery because they may be specifically targeted to tumors thereby shielding healthy organs from toxic side effects of incorporated drugs. Passive targeting of liposomes is achieved through the inclusion of PEG to evade the RES and prolong circulation in the bloodstream. Since tumor vasculature exhibits increased permeability, prolonged circulation results in passive accumulation of liposomes to tumor. Active targeting is accomplished through the inclusion of agents targeted to over-expressed receptors on tumor cells. In vitro studies have demonstrated increased cytotoxicity of actively targeted liposomes due to specific uptake by tumor cells. In vivo, however, actively targeted liposomal nanocarriers have failed to meet the expectations established by the promising outcomes of in vitro studies. This is attributed to the fact that the inclusion of targeting agents results in accelerated clearance from the bloodstream and reductions in passive targeting to tumor thereby offsetting the benefits of active targeting. The central focus of this thesis was to engineer a multi-functional nanoscale drug delivery system which would enable active targeting without compromising RES evasion and passive accumulation to tumor. It was shown that the use of folate in liposomal formulations significantly reduced blood circulation times. To prevent RES recognition of folate on targeted liposomal formulations, a cysteine cleavable phospholipid-PEG conjugate was utilized to "mask" targeting ligands while liposomes were in circulation. Once passive accumulation at the tumor was achieved, cysteine was administered to detach PEG chains, expose folate, and promote uptake by tumor cells. In vivo studies demonstrated that cleavable DSPE-PEG5000 was capable of concealing folate on liposomes to maintain prolonged circulation times. In vitro studies verified the ability to conceal and expose folate on demand, permitting receptor mediated targeting and delivery of drug to target cells. Studies conducted to analyze drug uptake by tumor cells in vivo confirmed that delivery was enhanced when tumor-inoculated animals received targeted liposomes containing cleavable PEG chains followed by a cysteine infusion to expose folate. These results indicate that detachable PEG chains can be used in targeted liposomal formulations to enhance efficacy of chemotherapy in the treatment of glioma.

Le virus de l'hépatite C (VHC) est une cause majeure d'affection hépatique chronique, notamment la cirrhose et le cancer du foie. On estime que 170 millions de personnes dans le monde sont des porteurs chroniques du VHC et que 3 à 4 millions de personnes sont infectées chaque année. Un des handicaps majeurs de la recherche sur le VHC est l'absence de systèmes de culture in vitro efficaces et de modèles animaux. Nous avons ainsi choisi une approche recombinante pour l'étude de protéines E1, E2 et p7 du VHC.Les protéines E1, E2 et p7 qui sont impliquées dans des étapes essentielles du cycle viral sont des protéines membranaires. Cependant, l'expression recombinante de cette classe de protéine est extrêmement complexe. En effet, la surexpression des protéines membranaires est souvent toxique pour les cellules hôtes. Ce phénomène est provoqué par l'agrégation ou la dégradation des protéines dans le cytoplasme dû à un manque de membrane disponible pour assurer leur intégration sur la cellule hôte. De plus, la surexpression de protéines membranaires induit la saturation de la machinerie cellulaire liée aux protéines membranaires. Ce détournement empêche le déroulement d'un cycle cellulaire normal et est ainsi fatal pour la cellule hôte. La forte concentration de protéines membranaires ou encore le fait que celles-ci soient hétérologues peut également provoquer la déstabilisation de la membrane de la cellule hôte et de son homéostasie. Afin de nous affranchir de ces limitations, nous avons utilisé une méthode de production des protéines membranaires sous forme native par un système acellulaire en présence de liposomes ; une technologie brevetée par l'université Joseph Fourier et exploitée par la société Synthelis. Dans un premier temps, nous avons procédé à la mise en place du système de production exploitant un lysat bactérien d'E. coli et d'un mélange énergétique complémentaire. Nous avons ensuite utilisé ce system pour étudier la viroporine p7. Cette protéine est essentielle pour la production de particules virales infectieuses et est impliquée dans l'assemblage viral ce qui en fait une cible thérapeutique intéressante. La production de protéoliposomes p7 en grande quantité nous a permis la caractérisation de la protéine par des techniques biochimiques et biophysiques. Nous avons mis en évidence l'inhibition de l'oligomérisation de p7 par le HMA qui ainsi inhibe sa fonction canal ionique. Grâce à la flexibilité du système d'expression acellulaire nous avons caractérisé la structure de la viroporine dans la membrane par réflectivité de neutron et avons confirmé la forme en entonnoir du complexe protéique. Des résultats préliminaires sur les proéoliposomes E1E2 quant à eux permettent d'espérer la production prochaine de particules virales mimant le VHC afin de mieux l'étudier et de lutter contre cette épidémie.L'ensemble de ces résultats confirment la pertinence de l'expression de protéines membranaires sous formes natives en système acellulaire en présence de liposomes. Les protéoliposomes produits constituent des nouveaux outils pour l'étude du VHC et permettent d'envisager de très grandes applications thérapeutiques ainsi que le développement de biomédicaments basés sur l'utilisation de protéines membranaires recombinantes. / The Hepatitis C virus (HCV) is a major cause of chronic liver disease, including cirrhosis and liver cancer. An estimated 170 million people worldwide are chronically infected with HCV and 3 to 4 million people are infected each year. One of the major handicaps of the HCV research is the lack of effective in vitro culture systems and animal models. To adress this issue, we chose a recombinant approach to study the E1, E2 and p7 proteins of HCV.The E1, E2 and p7 proteins are involved in critical steps of the viral cycle. They are membrane proteins, a class of protein that is extremely complex to express. Indeed, overexpression of membrane proteins is often toxic to the host cells. This phenomenon is caused by protein aggregation or degradation in the cytoplasm due to a lack of available membrane space for their integration into the host cell. Moreover, overexpression of membrane proteins induces saturation of the cellular machinery linked to membrane proteins. This diversion prevents the flow of a normal cell cycle and is fatal to the host cell. Destabilization of the host cell's membrane and its homeostatis may also be caused by the high concentration of membrane proteins or their heterologous nature. To circumvent these limitations, we used a method for producing membrane proteins in their native form by a cell-free system in the presence of liposomes; a technology patented by the University Joseph Fourier and licenced by the startup company Synthelis. First, we have set up the cell-free production system using a bacterial lysate from E. coli and a complementary energy mix. We then used this system to study the p7 viroporine. This protein is essential for the production of infectious virus particles and is involved in viral assembly making it an attractive therapeutic target. The production of a large quantity of p7 proteoliposomes allowed us to characterize the protein by biochemical and biophysical techniques. We have demonstrated the inhibition of oligomerization of p7 by HMA, which thereby inhibits its ion channel function. Thanks to the flexibility of the cell-free expression system we have characterized the structure of the viroporine within the membrane in a neutron reflectivity assay and have confirmed the funnel shape of the protein complex. Preliminary results on proteoliposomes E1E2 offer hope for the production viral particles mimicking the hepatitis C virus in order to better study the virus and fight against this epidemic.Together, these results confirm the suitability of the expression of membrane proteins in native forms using a cell-free system in the presence of liposomes. Proteoliposomes products are a new tool for the study of HCV and consideration for very broad therapeutic applications and the development of biopharmaceuticals based on the use of recombinant membrane proteins.